IBD research smashes recruitment target two years early
In the UK, at least 300,000 people are affected by Crohn’s disease or ulcerative colitis.
Read More
Author: Anna Smith
Novartis announces positive results from two Entresto trials
Heart failure is a chronic and progressive condition, which impacts 26 million people worldwide.
Read More
C4X forms Drug Discovery Advisory Network
The team will act as ambassadors for C4XD within the Biotech and Pharmaceutical community.
Read More
Xofluza effective as preventative flu medicine
Xofluza is the first and only one-dose oral medicine approved to treat flu in otherwise healthy patients.
Read More
Brilinta reduces CV events but increases bleeding
The drug reduced the relative risk for the composite of cardiovascular death, heart attack, or stroke by 10% compared with aspirin alone.
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
